VANCOMYCIN AND PIPERACILLIN-TAZOBACTAM OR CEFEPIME AND SEPSIS-ASSOCIATED AKI TRAJECTORY

被引：0
|
作者：
Behal, Michael [1 ]
Whitenack, Kaylee [2 ]
Bastin, Melissa Thompson [3 ]
Adams, Paul [1 ]
Aycinena, Juan Carlos [3 ]
Flannery, Alexander [2 ]
机构：
[1] Univ Kentucky, Lexington, KY USA
[2] Univ Kentucky, Coll Pharm, Lexington, KY USA
[3] Univ Kentucky HealthCare, Lexington, KY USA
来源：
CRITICAL CARE MEDICINE | 2023年 / 51卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
42
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [21] Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults
    Chanderraj, Rishi
    Dickson, Robert P.
    Sjoding, Michael W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (08):
  • [22] The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime
    Molina, Kyle C.
    Barletta, Jeffrey F.
    Hall, Scott T.
    Yazdani, Cyrus
    Huang, Vanthida
    JOURNAL OF INTENSIVE CARE MEDICINE, 2020, 35 (12) : 1434 - 1438
  • [23] Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem
    Rungkitwattanakul, Dhakrit
    Ives, Amy L.
    Harriott, Nicole G.
    Pan-Chen, Sarah
    Lan Duong
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (02) : 103 - 109
  • [24] Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study
    Cook, Kathryn M.
    Gillon, Jessica
    Grisso, Alison G.
    Banerjee, Ritu
    Jimenez-Truque, Natalia
    Phillips, Elizabeth J.
    Van Driest, Sara L.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2019, 8 (03) : 221 - 227
  • [25] Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill Reply
    Schreier, Diana J.
    Rule, Andrew D.
    Barreto, Erin F.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1521 - 1521
  • [26] Nephrotoxicity of vancomycin increased when combined with piperacillin-tazobactam
    Reactions Weekly, 2022, 1922 (1) : 11 - 11
  • [27] Piperacillin/tazobactam: no increased risk of AKI without vancomycin
    Reactions Weekly, 2020, 1815 (1) : 9 - 9
  • [28] Risk of acute kidney injury in critically-Ill patients receiving concomitant vancomycin and piperacillin-tazobactam compared to vancomycin and cefepime
    Molina, Kyle
    Yazdani, Cyrus
    Barletta, Jeffrey
    Hall, Scott
    Huang, Vanthida
    PHARMACOTHERAPY, 2017, 37 (12): : E150 - E150
  • [29] Incidence of Acute Kidney Injury (AKI) in Critically Ill Patients Receiving Concomitant Vancomycin with Piperacillin-Tazobactam or Cefepime; a Systemic Review and Meta-analysis
    Alaradi, Lamees
    Albariqi, Nada
    Alanazi, Mona
    Alghassab, Naif
    Aseri, Tief
    Alahmadi, Lujain
    Alahmadi, Ahmad
    Althobaiti, Aseel
    Alqarafi, Yousef
    Bokhari, Habeeba
    Qutob, Rayan A.
    Almaimani, Mohanad
    JOURNAL OF INTENSIVE CARE MEDICINE, 2025,
  • [30] The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW)
    Al-Jebawi, Y.
    Karalic, K.
    Shekhawat, P.
    Mhanna, M. J.
    JOURNAL OF NEONATAL-PERINATAL MEDICINE, 2022, 15 (02) : 303 - 309
12345